TY  - JOUR
AU  - Tolić, Anja
AU  - Ravichandran, Mirunalini
AU  - Rajić, Jovana
AU  - Đorđević, Marija
AU  - Đorđević, Miloš
AU  - Dinić, Svetlana
AU  - Grdović, Nevena
AU  - Arambašić Jovanović, Jelena
AU  - Mihailović, Mirjana
AU  - Nestorović, Nataša
AU  - Jurkowski, Tomasz P.
AU  - Uskoković, Aleksandra
AU  - Vidaković, Melita
PY  - 2022
UR  - https://epigeneticsandchromatin.biomedcentral.com/articles/10.1186/s13072-022-00445-8
UR  - http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=PMC8985375
UR  - http://radar.ibiss.bg.ac.rs/handle/123456789/4957
AB  - BACKGROUND Poly(ADP-ribosyl)ation (PARylation), a posttranslational modification introduced by PARP-1 and PARP-2, has first been implicated in DNA demethylation due to its role in base excision repair. Recent evidence indicates a direct influence of PARP-dependent PARylation on TET enzymes which catalyse hydroxymethylation of DNA-the first step in DNA demethylation. However, the exact nature of influence that PARylation exerts on TET activity is still ambiguous. In our recent study, we have observed a negative influence of PARP-1 on local TET-mediated DNA demethylation of a single gene and in this study, we further explore PARP-TET interplay. RESULTS Expanding on our previous work, we show that both TET1 and TET2 can be in vitro PARylated by PARP-1 and PARP-2 enzymes and that TET1 PARylation negatively affects the TET1 catalytic activity in vitro. Furthermore, we show that PARylation inhibits TET-mediated DNA demethylation at the global genome level in cellulo. CONCLUSIONS According to our findings, PARP inhibition can positively influence TET activity and therefore affect global levels of DNA methylation and hydroxymethylation. This gives a strong rationale for future examination of PARP inhibitors' potential use in the therapy of cancers characterised by loss of 5-hydroxymethylcytosine.
PB  - London: BioMed Central Ltd
T2  - Epigenetics & Chromatin
T1  - TET-mediated DNA hydroxymethylation is negatively influenced by the PARP-dependent PARylation.
IS  - 1
VL  - 15
DO  - 10.1186/s13072-022-00445-8
SP  - 11
ER  - 

@article{
author = "Tolić, Anja and Ravichandran, Mirunalini and Rajić, Jovana and Đorđević, Marija and Đorđević, Miloš and Dinić, Svetlana and Grdović, Nevena and Arambašić Jovanović, Jelena and Mihailović, Mirjana and Nestorović, Nataša and Jurkowski, Tomasz P. and Uskoković, Aleksandra and Vidaković, Melita",
year = "2022",
abstract = "BACKGROUND Poly(ADP-ribosyl)ation (PARylation), a posttranslational modification introduced by PARP-1 and PARP-2, has first been implicated in DNA demethylation due to its role in base excision repair. Recent evidence indicates a direct influence of PARP-dependent PARylation on TET enzymes which catalyse hydroxymethylation of DNA-the first step in DNA demethylation. However, the exact nature of influence that PARylation exerts on TET activity is still ambiguous. In our recent study, we have observed a negative influence of PARP-1 on local TET-mediated DNA demethylation of a single gene and in this study, we further explore PARP-TET interplay. RESULTS Expanding on our previous work, we show that both TET1 and TET2 can be in vitro PARylated by PARP-1 and PARP-2 enzymes and that TET1 PARylation negatively affects the TET1 catalytic activity in vitro. Furthermore, we show that PARylation inhibits TET-mediated DNA demethylation at the global genome level in cellulo. CONCLUSIONS According to our findings, PARP inhibition can positively influence TET activity and therefore affect global levels of DNA methylation and hydroxymethylation. This gives a strong rationale for future examination of PARP inhibitors' potential use in the therapy of cancers characterised by loss of 5-hydroxymethylcytosine.",
publisher = "London: BioMed Central Ltd",
journal = "Epigenetics & Chromatin",
title = "TET-mediated DNA hydroxymethylation is negatively influenced by the PARP-dependent PARylation.",
number = "1",
volume = "15",
doi = "10.1186/s13072-022-00445-8",
pages = "11"
}

Tolić, A., Ravichandran, M., Rajić, J., Đorđević, M., Đorđević, M., Dinić, S., Grdović, N., Arambašić Jovanović, J., Mihailović, M., Nestorović, N., Jurkowski, T. P., Uskoković, A.,& Vidaković, M.. (2022). TET-mediated DNA hydroxymethylation is negatively influenced by the PARP-dependent PARylation.. in Epigenetics & Chromatin
London: BioMed Central Ltd., 15(1), 11.
https://doi.org/10.1186/s13072-022-00445-8

Tolić A, Ravichandran M, Rajić J, Đorđević M, Đorđević M, Dinić S, Grdović N, Arambašić Jovanović J, Mihailović M, Nestorović N, Jurkowski TP, Uskoković A, Vidaković M. TET-mediated DNA hydroxymethylation is negatively influenced by the PARP-dependent PARylation.. in Epigenetics & Chromatin. 2022;15(1):11.
doi:10.1186/s13072-022-00445-8 .

Tolić, Anja, Ravichandran, Mirunalini, Rajić, Jovana, Đorđević, Marija, Đorđević, Miloš, Dinić, Svetlana, Grdović, Nevena, Arambašić Jovanović, Jelena, Mihailović, Mirjana, Nestorović, Nataša, Jurkowski, Tomasz P., Uskoković, Aleksandra, Vidaković, Melita, "TET-mediated DNA hydroxymethylation is negatively influenced by the PARP-dependent PARylation." in Epigenetics & Chromatin, 15, no. 1 (2022):11,
https://doi.org/10.1186/s13072-022-00445-8 . .

TY  - CHAP
AU  - Vidaković, Melita
AU  - Tolić, Anja
AU  - Grdović, Nevena
AU  - Ravichandran, Mirunalini
AU  - Jurkowski, Tomasz P.
PY  - 2019
UR  - https://link.springer.com/referenceworkentry/10.1007%2F978-3-319-55530-0_55
UR  - https://radar.ibiss.bg.ac.rs/handle/123456789/3616
AB  - Diabetes and diabetic complications, autoimmunity and inflammatory diseases, have recently become the focus of epigenetic therapy, since with epigenetic drugs it is possible to reverse aberrant gene expression profiles associated with the disease states. For diabetes, the therapy challenges depend on identifying the most appropriate molecular target and its influence on a relevant gene product. This chapter summarizes the current view on the interplay between ten-eleven translocation (TETs) and the poly(ADP-ribose) polymerase (PARPs) family of enzymes in regulating DNA methylation and how this interplay could be targeted to attenuate diabetes. This molecular interchange jigsaw puzzle is emerging as an important focus of research, and we can expect to see further advances in the elucidation of its role in diabetes as well as other pathologies. Moreover, the possibility for designating specific PARP-1 inhibitors as potential “EPI-drugs” for diabetes prevention/attenuation is also discussed. Understanding the epigenetic machinery and the differential roles of its components is essential for the development of targeted epigenetic therapies for diseases.
PB  - Springer International Publishing
T2  - Handbook of Nutrition, Diet, and Epigenetics
T1  - PARylation, DNA (De)methylation, and Diabetes
DO  - 10.1007/978-3-319-55530-0_55
SP  - 1857
EP  - 1876
ER  - 

@inbook{
author = "Vidaković, Melita and Tolić, Anja and Grdović, Nevena and Ravichandran, Mirunalini and Jurkowski, Tomasz P.",
year = "2019",
abstract = "Diabetes and diabetic complications, autoimmunity and inflammatory diseases, have recently become the focus of epigenetic therapy, since with epigenetic drugs it is possible to reverse aberrant gene expression profiles associated with the disease states. For diabetes, the therapy challenges depend on identifying the most appropriate molecular target and its influence on a relevant gene product. This chapter summarizes the current view on the interplay between ten-eleven translocation (TETs) and the poly(ADP-ribose) polymerase (PARPs) family of enzymes in regulating DNA methylation and how this interplay could be targeted to attenuate diabetes. This molecular interchange jigsaw puzzle is emerging as an important focus of research, and we can expect to see further advances in the elucidation of its role in diabetes as well as other pathologies. Moreover, the possibility for designating specific PARP-1 inhibitors as potential “EPI-drugs” for diabetes prevention/attenuation is also discussed. Understanding the epigenetic machinery and the differential roles of its components is essential for the development of targeted epigenetic therapies for diseases.",
publisher = "Springer International Publishing",
journal = "Handbook of Nutrition, Diet, and Epigenetics",
booktitle = "PARylation, DNA (De)methylation, and Diabetes",
doi = "10.1007/978-3-319-55530-0_55",
pages = "1857-1876"
}

Vidaković, M., Tolić, A., Grdović, N., Ravichandran, M.,& Jurkowski, T. P.. (2019). PARylation, DNA (De)methylation, and Diabetes. in Handbook of Nutrition, Diet, and Epigenetics
Springer International Publishing., 1857-1876.
https://doi.org/10.1007/978-3-319-55530-0_55

Vidaković M, Tolić A, Grdović N, Ravichandran M, Jurkowski TP. PARylation, DNA (De)methylation, and Diabetes. in Handbook of Nutrition, Diet, and Epigenetics. 2019;:1857-1876.
doi:10.1007/978-3-319-55530-0_55 .

Vidaković, Melita, Tolić, Anja, Grdović, Nevena, Ravichandran, Mirunalini, Jurkowski, Tomasz P., "PARylation, DNA (De)methylation, and Diabetes" in Handbook of Nutrition, Diet, and Epigenetics (2019):1857-1876,
https://doi.org/10.1007/978-3-319-55530-0_55 . .